The Phase III study saw the drug able to cut risk of death by 38% with imlunestrant alone, and down so far as 43% with Verzenio.

AnaptysBio has reported that the ARISE-AD trial of ANB032, for treating moderate-to-severe atopic dermatitis failed to meet both endpoints.

The inMIND trial results have elevated expectations for Monjuvi's commercial success, but competition is on the horizon.

Results from the company’s Phase I trial found its prodrug, SPT-300, was well tolerated, opening the doors to a Phase IIb trial ...